“Couple’s Immunotherapy”: Is CXCL13 at the Heart of the Prescription?-Reference-Cited by-同舟云学术

“Couple’s Immunotherapy”: Is CXCL13 at the Heart of the Prescription?

Published:2024-07-05 Issue:8 Volume:12 Page:952-953
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:

Author:

Cruz-Hinojoza Eduardo¹²^ORCID,Stromnes Ingunn M.¹²³⁴^ORCID

Affiliation:

1. Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota. 1

2. Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota. 2

3. Center for Genome Engineering, University of Minnesota Medical School, Minneapolis, Minnesota. 3

4. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 4

Abstract

Sex differences in cancer survivorship and response to immunotherapy have been observed, with males generally displaying better outcomes to immune checkpoint blockade compared with females. In this article, by interrogating public lung cancer sequencing datasets, Brennan and colleagues uncover a chemokine axis that may contribute to disparate immunotherapy outcomes between the sexes. See related article by Brennan et al., p. 956 (3).

Funder

NIH

ACS

DOD

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/cancerimmunolres/article-pdf/doi/10.1158/2326-6066.CIR-24-0481/3472102/cir-24-0481.pdf

Reference5 articles.

1. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade;Morad;Cell,2021

2. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications;Xiao;Nat Rev Cancer,2024

3. T-cell expression of CXCL13 is associated with immunotherapy response in a sex-dependent manner in patients with lung cancer;Brennan;Cancer Immunol Res,2024

4. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion;Conforti;Clin Cancer Res,2021

5. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma;Park;Cancer Med,2023